Aktie 6785 ALAR PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Alar Pharmaceuticals Inc.

Aktien

6785

TW0006785009

6785

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 26.06.2024 		% 5 Tage % 1. Jan.
250,5 TWD +2,04 % Intraday Chart für Alar Pharmaceuticals Inc. +1,62 % +19,57 %
10.05. Alar Pharmaceuticals Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
14.03. Alar Pharmaceuticals Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023, Payable on June 28, 2024
Gilva Therapeutics, INC. announced that it expects to receive TWD 30 million in funding from Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
Alar Pharmaceuticals Inc.(TPEX:6785) added to S&P Global BMI Index
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 6785 Aktie
  4. Nachrichten Alar Pharmaceuticals Inc.
  5. Andere Sprachen